Short-term Efficacy of Narivent® in the Treatment of Nasal Congestion

Valerio Damiani1, Angelo Camaioni1, Claudio Viti1, Giulia Schillani2, Francesca Foltran3, Antonella Silvia Scire4, Giada Morpurgo4, Dario Gregori3, *
1 ENT Department San Giovanni Addolorata Hospital, Rome, Italy
2 Department of Life Sciences, University of Trieste, Italy
3 Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Italy
4 Zeta Research Srl, Trieste, Italy

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 429
Abstract HTML Views: 496
PDF Downloads: 8
Total Views/Downloads: 933
Unique Statistics:

Full-Text HTML Views: 250
Abstract HTML Views: 323
PDF Downloads: 8
Total Views/Downloads: 581

© 2012 Damiani et al.;

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Correspondence: * Address correspondence to this author at the Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic and Vascular Sciences, Via Loredan, 18, 35121 Padova – Italy. Tel: +39 049 8275384; Fax: +39 02 700445089; E-mail:


Rationale and aim:

Nasal congestion is a common symptom in rhinologic diseases such as rhinosinusitis, nasal polyposis and adenoid pathology. Although various pharmacotherapy options exist, no agent is universally efficacious. The aim of this study was to evaluate the efficacy of Narivent®, an osmotically acting medical device with antioedematous and anti-inflammatory effects, in a short-term (7days) treatment.


A single-centre prospective study with a pre-post design was conducted with consecutive enrolment in an Italian Otolaryngology Department of 36 both genders patients with nasal congestion. Patients received 2 puffs of Narivent® into each nostril 2 times a day over the course of 1 week. The severity of symptoms was assessed subjectively as measured by a 0 to 10 visual analogue scale (VAS) and the presence/absence of symptoms and signs. Differences in subjective and objective severity measures before and after treatment were compared using Paired-Sample Wilcoxon Signed Rank Test.


A significant improvement after treatment (p<0.001) has been recorded for the main subjective symptoms and objective signs (overall symptom burden, nasal congestion, cephalea, turbinates hypertrophy, normal mucosa status).


Study results confirm the efficacy of Narivent® in treating nasal congestion over a 1 week period.

Keywords: nasal congestion, osmotically acting medical device, anti-oedematous activity.